US Patent 7655226 Treatment of Pompe's disease
Patent 7655226 was granted and assigned to Genzyme on February, 2010 by the United States Patent and Trademark Office.
All edits
Edits on 30 Oct, 2023
Golden AI
Edits made to:
Article (+219 characters)
Article
Patent abstract
The invention provides methods of treating Pompe's disease using human acid alpha glucosidase. A preferred treatment regime comprises administering greater than 10 mg/kg body weight per week to a patient.
Edits on 17 Sep, 2023
Golden AI
Edits made to:
Infobox (+3 properties)
Infobox
Patent Inventor Names
David P. Meeker0
Edna H. G. Venneker0
Johannes B. M. M. Van Bree0
Edits on 13 Sep, 2023
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 24 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07655226 Treatment of Pompe's disease US Patent 7655226 Treatment of Pompe's disease
Infobox
Patent Number
076552260
Patent Number
76552260
Edits on 22 May, 2023
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 23 Sep, 2022
Golden AI
Infobox
Is a
Current Assignee
Patent Jurisdiction
Patent Number
076552260
Date of Patent
February 2, 2010
0Patent Application Number
120120030
Date Filed
January 30, 2008
0Official Website
Patent Primary Examiner
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 3 Dec, 2021
Golden AI
Edits made to:
Infobox (+8 properties)
US Patent 07655226 Treatment of Pompe's disease
Infobox
Is a
Current assignee
Patent jurisdiction
Patent number
07655226
Date of patent
February 2, 2010
Patent application number
12012003
Date Filed
January 30, 2008
Patent primary examiner
Find more entities like US Patent 7655226 Treatment of Pompe's disease
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
